Last reviewed · How we verify

NCT06895681

UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations

Not yet recruiting Last updated 10 November 2025
What this trial tests

trial testing Blood Sample in Solid Tumor in 50,000 participants. Not yet recruiting.

Timeline
31 January 2026
Primary endpoint
31 December 2035
31 December 2035

Quick facts

Lead sponsorUniversity of California, San Francisco
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment50,000
Start date31 January 2026
Primary completion31 December 2035
Estimated completion31 December 2035
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of California, San Francisco

Who can join

18 and older, any sex, with Solid Tumor or Solid Tumor, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a non-therapeutic clinical research biorepository protocol designed to obtain, store, and clinically annotate biospecimens from participants with hereditary cancers. Those biospecimens will be used to generate participant-derived tumor models that will serve as a resource to better understand hereditary cancers and develop new efficient therapies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood Sample

Trials testing the same drug.

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

Other University of California, San Francisco trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06895681.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing